Diagnocure Inc (DGCRF) 0.1290 $DGCRF
DiagnoCure announces results for third quarter of 2014
PR Newswire - Thu Sep 11, 4:01PM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the third quarter 2014 ended July 31, 2014. The Corporation announced a net loss of $504,105 or $0.01 per share for this quarter compared with a loss of $595,262 or $0.01 per share for the same period last year. During the third quarter ended July 31, 2014, total revenues decreased by 19% compared with the same quarter of 2013, due to a decrease in PCA3 royalties paid to DiagnoCure. Operating expenses decreased by $127,318 or 16%, to $657,529 for the third quarter of 2014 from $784,847 for the same period of 2013. At the end of the quarter, cash and short-term investments stood at $2,541,852.
DiagnoCure Announces First Quarter 2014 Results
PR Newswire - Fri Mar 14, 4:22PM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the first quarter 2014 ended January 31, 2014. The Corporation announced a net loss of $529,739 or $0.01 per share for this quarter. At the end of the quarter, cash, cash equivalents and short-term investments stood at $3,543,029.
DiagnoCure announces fourth quarter 2013 and year-end results
CNW Group - Thu Jan 16, 3:00PM CST
Providing Corporate Update on Key Projects
Allstate Looking to Add at Least 550 Sales Jobs in Seven States in 2014
Michael Buck - AMBest - Tue Jan 14, 2:04PM CST
Allstate Corp. is expanding its sales force in three Midwest and four Southwest states, looking to add at least 550 new positions this year, according to written statements from the company.
Stroock Names Three New Partners
PR Newswire - Tue Jan 07, 9:30AM CST
Stroock & Stroock & Lavan LLP, a national law firm with offices in New York, Los Angeles, Miami and Washington, DC, named three new partners, effective January 1, 2014.
Diagnocure Grants Stock Options To Senior Advisor
CNW Group - Tue Sep 17, 6:30AM CDT
Vesting Linked To Improvement of Shareholder Value
DiagnoCure announces third quarter 2013 results
CNW Group - Wed Sep 04, 3:00PM CDT
Strong Royalty Revenues Increase of 39 % from Hologic Gen-Probe partnership
DiagnoCure to host Q3 2013 earnings conference call and webcast
PR Newswire - Tue Aug 27, 6:30AM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) announced today that it will release its third quarter 2013 results on September 4, 2013, at 4:00 p.m. (EDT). DiagnoCure's management will host a conference call the same day, at 4:30 p.m. (EDT). Interested participants may listen to the call by dialing 1-888-390-0546 or 514-225-6995 and referencing code 78274536 approximately 15 minutes prior to the call. The Corporation will also provide a live webcast of the call. Interested participants may access the webcast on DiagnoCure's website at www.diagnocure.com, through a link on the Investors page- Presentations. A replay of the webcast will be available on DiagnoCure's website for those unable to participate in the live webcast.
DiagnoCure appoints Richard Bordeleau as Senior Advisor to the board
CNW Group - Tue Aug 20, 6:30AM CDT
Appointment Targeting Next Steps to Increasing Shareholder Value
Cancer Diagnostics: A Global Analysis - Report Includes Dollar Volume of Sales For Tumor Marker Testing Equipment by Market and Discusses Competitors In-Depth
M2 - Thu Jul 18, 12:12PM CDT
Research and Markets (http://www.researchandmarkets.com/research/pp2l5q/cancer_diagnostic) has announced the addition of the "Cancer Diagnostics: A Global Analysis" report to their offering. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Some of the companies mentioned include: - Abbott Diagnostics - Beckman Coulter, Inc. - Clarient, Inc. - DiagnoCure, Inc. - Enigma Diagnostics Ltd. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Hologic, Inc. (formerly Cytyc Corporation) - Immunicon Corporation (now Veridex, LLC) - LabCorp - Matritech - Nuvelo, Inc. - Oncotech, Inc. - Polymedco, Inc. - Qiagen - Roche (F. Hoffman-La Roche, Ltd.) - Siemens Heathcare Diagnostics - Tosoh Corporation (Bioscience division) - Veridex, LLC - Vermillion, Inc. - Worldwide Medical Corporation - Xenomics, Inc. (TrovaGene, Inc.) For more information visit and a full list of the companies mentioned in this report go to http://www.researchandmarkets.com/research/pp...diagnostic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DiagnoCure announces second quarter 2013 results
PR Newswire - Mon Jun 03, 3:01PM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the second quarter ended April 30, 2013. The Corporation announced a net loss of $849,344 or $0.02 per share for this quarter. At the end of the quarter, cash and short-term investments stood at $4,849,305.
Data From a New Study on Diagnocure's GCC Assay Show Positive Results for Predicting Risk of Colon Cancer Recurrence
CNW Group - Mon Jun 03, 6:30AM CDT
Previstage(TM)GCC colorectal cancer test featured at the 2013 ASCO Annual Meeting
DiagnoCure announces results for third quarter of 2014
PR Newswire - Thu Sep 11, 4:01PM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the third quarter 2014 ended July 31, 2014. The Corporation announced a net loss of $504,105 or $0.01 per share for this quarter compared with a loss of $595,262 or $0.01 per share for the same period last year. During the third quarter ended July 31, 2014, total revenues decreased by 19% compared with the same quarter of 2013, due to a decrease in PCA3 royalties paid to DiagnoCure. Operating expenses decreased by $127,318 or 16%, to $657,529 for the third quarter of 2014 from $784,847 for the same period of 2013. At the end of the quarter, cash and short-term investments stood at $2,541,852. DiagnoCure Announces First Quarter 2014 Results
PR Newswire - Fri Mar 14, 4:22PM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the first quarter 2014 ended January 31, 2014. The Corporation announced a net loss of $529,739 or $0.01 per share for this quarter. At the end of the quarter, cash, cash equivalents and short-term investments stood at $3,543,029. DiagnoCure announces fourth quarter 2013 and year-end results
CNW Group - Thu Jan 16, 3:00PM CST
Providing Corporate Update on Key Projects
Allstate Looking to Add at Least 550 Sales Jobs in Seven States in 2014
Michael Buck - AMBest - Tue Jan 14, 2:04PM CST
Allstate Corp. is expanding its sales force in three Midwest and four Southwest states, looking to add at least 550 new positions this year, according to written statements from the company.
Stroock Names Three New Partners
PR Newswire - Tue Jan 07, 9:30AM CST
Stroock & Stroock & Lavan LLP, a national law firm with offices in New York, Los Angeles, Miami and Washington, DC, named three new partners, effective January 1, 2014.
Diagnocure Grants Stock Options To Senior Advisor
CNW Group - Tue Sep 17, 6:30AM CDT
Vesting Linked To Improvement of Shareholder Value
DiagnoCure announces third quarter 2013 results
CNW Group - Wed Sep 04, 3:00PM CDT
Strong Royalty Revenues Increase of 39 % from Hologic Gen-Probe partnership
DiagnoCure to host Q3 2013 earnings conference call and webcast
PR Newswire - Tue Aug 27, 6:30AM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) announced today that it will release its third quarter 2013 results on September 4, 2013, at 4:00 p.m. (EDT). DiagnoCure's management will host a conference call the same day, at 4:30 p.m. (EDT). Interested participants may listen to the call by dialing 1-888-390-0546 or 514-225-6995 and referencing code 78274536 approximately 15 minutes prior to the call. The Corporation will also provide a live webcast of the call. Interested participants may access the webcast on DiagnoCure's website at www.diagnocure.com, through a link on the Investors page- Presentations. A replay of the webcast will be available on DiagnoCure's website for those unable to participate in the live webcast.
DiagnoCure appoints Richard Bordeleau as Senior Advisor to the board
CNW Group - Tue Aug 20, 6:30AM CDT
Appointment Targeting Next Steps to Increasing Shareholder Value
Cancer Diagnostics: A Global Analysis - Report Includes Dollar Volume of Sales For Tumor Marker Testing Equipment by Market and Discusses Competitors In-Depth
M2 - Thu Jul 18, 12:12PM CDT
Research and Markets (http://www.researchandmarkets.com/research/pp2l5q/cancer_diagnostic) has announced the addition of the "Cancer Diagnostics: A Global Analysis" report to their offering. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Some of the companies mentioned include: - Abbott Diagnostics - Beckman Coulter, Inc. - Clarient, Inc. - DiagnoCure, Inc. - Enigma Diagnostics Ltd. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Hologic, Inc. (formerly Cytyc Corporation) - Immunicon Corporation (now Veridex, LLC) - LabCorp - Matritech - Nuvelo, Inc. - Oncotech, Inc. - Polymedco, Inc. - Qiagen - Roche (F. Hoffman-La Roche, Ltd.) - Siemens Heathcare Diagnostics - Tosoh Corporation (Bioscience division) - Veridex, LLC - Vermillion, Inc. - Worldwide Medical Corporation - Xenomics, Inc. (TrovaGene, Inc.) For more information visit and a full list of the companies mentioned in this report go to http://www.researchandmarkets.com/research/pp...diagnostic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DiagnoCure announces second quarter 2013 results
PR Newswire - Mon Jun 03, 3:01PM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the second quarter ended April 30, 2013. The Corporation announced a net loss of $849,344 or $0.02 per share for this quarter. At the end of the quarter, cash and short-term investments stood at $4,849,305. Data From a New Study on Diagnocure's GCC Assay Show Positive Results for Predicting Risk of Colon Cancer Recurrence
CNW Group - Mon Jun 03, 6:30AM CDT
Previstage(TM)GCC colorectal cancer test featured at the 2013 ASCO Annual Meeting
